BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Moodys
UBS
Medtronic
Queensland Health
Daiichi Sankyo
Mallinckrodt
AstraZeneca
Chinese Patent Office
Boehringer Ingelheim

Generated: January 17, 2018

DrugPatentWatch Database Preview

Claims for Patent: 3,975,536

« Back to Dashboard

Summary for Patent: 3,975,536
Title: Composition
Abstract:There is described a composition comprising a substantially clear, sterile aqueous solution containing as active ingredient a therapeutically useful proportion of 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol, or a pharmaceutically acceptable (e.g. the di-sodium) salt thereof, or 5,5'-[[5,5'-(2-hydroxytrimethylene)dioxy]bis[4-oxo-4H-1-benzopyran-2-yl]]t etrazole, or a pharmaceutically acceptable (e.g. the di-sodium) salt thereof. The composition is indicated for the treatment of conditions of the eye and the nose.
Inventor(s): Stevenson; Neil Arthur (Loughborough, EN), Wardell; George (Loughborough, EN)
Assignee: Fisons Limited (London, EN)
Application Number:05/471,141
Patent Claims: 1. In a pharmaceutical composition which comprises a sterile aqueous solution containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically acceptable salt thereof as an active ingredient, the improvement according to which the said active ingredient is present in an amount of from 0.1 to 10% w/v, the said composition contains less than about 0.40 ppm of ions of metals in Groups IIa, Ib, IIb and IVb of the Periodic Table and of the transition metals, the said composition being a substantially clear, sterile aqueous solution.

2. A composition according to claim 1 which additionally contains from 0.001 to 0.10% w/v of a pharmaceutically acceptable preservative, said composition being made up by mixing an aqueous solution containing the 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically effective salt thereof with an aqueous solution containing the preservative and subjecting the thus obtained admixture to filtration.

3. A composition according to claim 2 containing from 0.001 to 0.5% w/v of sodium 2-(ethyl mercuriothio)benzoate.

4. A composition according to claim 2 wherein the preservative is a member selected from the group of compounds of the formula ##SPC2##

wherein R is alkyl C.sub.8 H.sub.17 to C.sub.18 H.sub.37, and a mixture of such compounds.

5. A composition according to claim 4 containing from 0.005 to 0.10% w/v of the preservative.

6. In a pharmaceutical composition which comprises a sterile aqueous solution containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically acceptable salt thereof as an active ingredient, the improvement according to which the said active ingredient is present in an amount of from 0.1 to 10% w/v, the composition contains less than about 20 ppm of ions of metals in Groups IIa, Ib, IIb and IVb of the Periodic Table and of the transition metals, the composition contains from about 0.05 to 0.1% w/v of a pharmaceutically acceptable chelating or sequestering agent, and the said composition being a substantially clear aqueous solution.

7. A composition according to claim 6 wherein the chelating or sequestering agent is ethylene diamine tetraacetic acid or a salt thereof.

8. A composition according to claim 6 which additionally contains from 0.001 to 0.10% w/v of a pharmaceutically acceptable preservative, said composition being made up by mixing an aqueous solution containing the 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically acceptable salt thereof and the chelating or sequestering agent with an aqueous solution containing the preservative and subjecting the thus obtained admixture to filtration.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Colorcon
US Army
Cipla
Fish and Richardson
McKinsey
Covington
Merck
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot